The market expects Axsome Therapeutics (AXSM) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2024, might help the stock move higher if these key numbers ar ...

AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative psychiatry and ...

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome's management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and provide a bus ...

Axsome Therapeutics, Inc. (AXSM) announced that it has initiated the phase III ENGAGE study evaluating its investigational therapy, solriamfetol, for treating adult patients with binge eating disorder (BED).Solriamfetol is presently marketed in the United States under the brand name Sunosi for the treatment of narcolepsy.The double-blind, placebo-controlled phase III study will evaluate the safety and efficacy of solriamfetol (150 mg or 300 mg) in adult patients with BED. The primary endpoint of the study i ...

Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks.Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics (AXSM -0.25%), CRISPR Therapeutics (CRSP -3.88%), and Pfizer (PFE -1.08%) as top picks for investors right now. Here's why they think buying these dirt-cheap stocks could be a brilliant move.The market continues to underestimate this stockProsper Junior Bakiny (Axsome Therapeutics): It's not easy to value relativ ...

A month has gone by since the last earnings report for Axsome Therapeutics (AXSM) . Shares have lost about 4% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Axsome’s Q4 Earnings & Revenue Surpass EstimatesA ...

Axsome Therapeutics, Inc. (AXSM) announced that it has dosed the first patient in the phase III PARADIGM study evaluating its investigational therapy, solriamfetol, for treating major depressive disorder (MDD). Shares of the company were up 6% on Mar 19, following the announcement of the news.Solriamfetol is marketed in the United States under the trade name, Sunosi, for the treatment of narcolepsy.The double-blind and placebo-controlled phase III study will evaluate the safety and efficacy of solriamfetol ...

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder (MDD). PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or ot ...

Axsome Therapeutics, Inc. (AXSM) reported an adjusted loss of 73 cents per share for the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $1.21. The company had reported a loss of $1.28 per share in the year-ago period.The above-adjusted loss excludes the impact of certain non-cash charges, including which the reported loss per share was $2.08 in the fourth quarter of 2023 compared with a loss of $1.41 reported in the year-ago quarter.The company’s fourth-quarter revenues were ...